Age-related macular degeneration patient receives investigational eye drops

Newswise — An 88-year-old man at The Methodist Hospital in Houston is one of two patients in the world today to receive an investigational eye drop that may restore sight for those suffering from neovascular (wet) age-related macular degeneration, a major cause of central visual loss and one of the leading causes of blindness in people over 60 in the United States.

Currently, the standard treatment requires multiple injections into the diseased eye.

Today, the patient received the topical administration of the drug called TG100801 in a Phase IIa, multi-center trial sponsored by TargeGen, Inc. This represents the first wet AMD patient in Texas and one of the first worldwide to be treated with eye drops alone for the management of the disease. In pre-clinical models, the investigational drug blocked new blood vessel growth and leakiness, which lead to AMD, by inhibiting VEGF and other related proteins that are believed to play a critical role in the formation of new blood vessels. TG100801 is also designed to reduce inflammation (including edema), a common symptom of AMD, and other back of the eye diseases, including diabetic macular edema and diabetic retinopathy. In as little as a month, investigators may learn if the eye drops were effective.

“If the eye drops work, it will be much better for the patient,” said Dr. David Brown, a retinal surgeon at Methodist and primary investigator at Vitreoretinal Consultants. “We’re continually looking for more effective treatments for our many AMD patients. If we can get this effect without injections, that would be a major breakthrough.”

AMD occurs in two forms: dry and wet. While all cases begin as the dry form, wet AMD accounts for about 85 percent of all AMD-related blindness and can result in sudden and severe vision loss. The dry form is associated with atrophic cell death of the central retina or macula.

The wet form is caused by growth of abnormal blood vessels that leak fluid and blood under the macula causing scar tissue that destroys the central retina. In 2006, the FDA approved the injectable drug Lucentis for wet AMD, based on data from two large Phase III clinical trials, in which Brown and his colleagues enrolled the most patients worldwide and published their data in the New England Journal of Medicine. Dry AMD, the most common form of the disease, represents approximately 85 to 90 percent of all AMD cases in the country. Currently, there is no FDA approved treatment for dry AMD.

Approximately 40 patients will be enrolled in the TargeGen Phase IIa trial in eight trial centers in the United States. For more information on the study at Methodist, call (713) 790-3333 or go to http://www.methodisthealth.com.

About The Methodist Hospital

The Methodist Hospital in Houston is one of the nation’s largest private, non-profit general hospitals. Dedicated to providing the highest level of patient care, Methodist has a 90 year legacy of medical breakthroughs, such as the world’s first multiple-organ transplant in the 1960s, gene therapy for prostate cancer, and the first islet cell transplants in Texas.

Methodist is ranked among the country’s top centers in 14 specialties in U.S News & World Report’s 2007 America’s Best Hospitals issue. The hospital ranked in more specialties than any other hospital in Texas. Methodist is also 9th on FORTUNE’s “100 Best Companies to Work For” in 2007.

Methodist is primarily affiliated with Weill Cornell Medical College and New York Presbyterian Hospital, two of the nation’s leading centers for patient care, medical education and research. Methodist also is affiliated with the University of Houston. For more information, call (713) 790-3333 or visit www.methodisthealth.com.

About TargeGen, Inc.

TargeGen, Inc. is a privately held vascular biology-focused biopharmaceutical company based in San Diego, CA. TargeGen is developing novel small molecule therapeutics to treat certain diseases involving vascular leakage, vascular proliferation, inflammation, and hematological malignancies by targeting certain biochemical processes associated with the formation and repair of blood vessels and vascular permeability (edema).